AFP and Candidemia: Two papers described a cohort of 95 recipients receiving AFP with isavuconazole, reporting a favorable safety profile (premature discontinuation: 15% isavuconazole vs. 44% voriconazole) [88], but a trend towards a higher incidence of b-IFDs (mostly candidemia) [88,90].